Condition (MeSH)
Lymphangiomyoma
ClinicalTrials.gov lists 48 trials for Lymphangiomyoma or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 48 trials are tagged with Lymphangiomyoma itself; the rest are tagged with a narrower condition beneath it.
When did Lymphangiomyoma trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 5 |
| 2017 | 2 |
| 2016 | 5 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lymphangiomyoma trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 5 |
| Phase 2 | 10 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 3 |
| Observational | 19 |
How many Lymphangiomyoma trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 10 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 28 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lymphangiomyoma trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 8 |
| Novartis Pharmaceuticals | 3 |
| CENTOGENE GmbH Rostock | 1 |
Which drugs are being tested for Lymphangiomyoma? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sirolimus | 6 |
| EVEROLIMUS | 5 |
| Imatinib | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| L01XE31 - Nintedanib | 1 |
| Letrozol (Femara, Novartis) | 1 |
| Rapamycin, sirolimus | 1 |
| albuterol nebulizer | 1 |
| Sirolimus Oral Product | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lymphangiomyoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pulmonary | 15 | 1 |
| Pain | 8 | 1 |
| Epilepsy | 6 | 1 |
| Pneumonia | 6 | 3 |
| Infection | 5 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Lymphangiomyoma? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis. | Molecular pharmacology | 2009 | Yes |
| Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. | American journal of respiratory and critical care medicine | 2001 | Yes |
| Lymphangiomyomatosis: CT, chest radiographic, and functional correlations. | Radiology | 1990 | Yes |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.